Your session is about to expire
← Back to Search
Proteasome Inhibitor
Mezigdomide Combo vs. Pomalidomide Combo for Multiple Myeloma (SUCCESSOR-1 Trial)
Phase 3
Recruiting
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights
SUCCESSOR-1 Trial Summary
This trial is testing a new combo - CC-92480, bortezomib, and dexamethasone - against the standard of care - pomalidomide, bortezomib, and dexamethasone - for patients with multiple myeloma who have failed 1-3 prior treatments and have been treated with lenalidomide before.
Who is the study for?
This trial is for people with Multiple Myeloma who've had 1-3 previous treatments and were previously treated with lenalidomide. They must have measurable disease, responded at least minimally to past therapy, and not have had a poor reaction or no response to bortezomib. Those who progressed on proteasome inhibitors recently or have been treated with mezigdomide/pomalidomide can't join.Check my eligibility
What is being tested?
The study compares two drug combinations for relapsed/refractory Multiple Myeloma: Mezigdomide with Bortezomib and Dexamethasone (MeziVd) versus Pomalidomide with the same additional drugs (PVd). It aims to see which combo works better after prior therapies including lenalidomide.See study design
What are the potential side effects?
Possible side effects include reactions related to immune system suppression such as infections, blood clots, fatigue, gastrointestinal issues like nausea or constipation, nerve damage that may cause pain or numbness, and potential blood cell count changes leading to anemia or bleeding risks.
SUCCESSOR-1 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression-free Survival (PFS)
Secondary outcome measures
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
Complete Response (CR) or better
+12 moreSUCCESSOR-1 Trial Design
2Treatment groups
Experimental Treatment
Group I: PVd (pomalidomide, bortezomib and dexamethasone)Experimental Treatment3 Interventions
Group II: MeziVd (mezigdomide, bortezomib and dexamethasone)Experimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2590
Pomalidomide
2011
Completed Phase 2
~1020
Bortezomib
2005
Completed Phase 2
~1140
Find a Location
Who is running the clinical trial?
CelgeneLead Sponsor
636 Previous Clinical Trials
128,044 Total Patients Enrolled
142 Trials studying Multiple Myeloma
40,053 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbLead Sponsor
2,640 Previous Clinical Trials
4,128,654 Total Patients Enrolled
87 Trials studying Multiple Myeloma
29,110 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had 1 to 3 treatments for my myeloma.I have shown improvement after receiving treatment for myeloma.I stopped using bortezomib due to side effects or did not respond well to it.My condition worsened during or soon after my last proteasome inhibitor treatment, but not with low-frequency bortezomib.I have been treated with mezigdomide or pomalidomide before.I have been diagnosed with multiple myeloma and it can be measured.Your M-protein levels are higher than a certain amount in your blood or urine.I have shown improvement after receiving treatment for myeloma.I have had 1 to 3 treatments for my myeloma.If you don't have any measurable disease in your blood or urine, your free light chain levels and kappa/lambda FLC ratio are abnormal.
Research Study Groups:
This trial has the following groups:- Group 1: PVd (pomalidomide, bortezomib and dexamethasone)
- Group 2: MeziVd (mezigdomide, bortezomib and dexamethasone)
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What has been observed in patients taking CC-92480?
"There is both preclinical and clinical evidence supporting CC-92480's safety, thus it received a score of 3."
Answered by AI
Could you name how many places this research project is being conducted?
"Patients can be enrolled at the Local Institution in Hattiesburg, Mississippi, Utah Cancer Specialists in Salt Lake City, Utah, Northwell Health Clinical Trials Office in Lake Success, New york, and 18 other locations."
Answered by AI
Can people sign up for this research project at the present moment?
"This study, as indicated on clinicaltrials.gov, is currently seeking participants. The trial was originally posted on September 20th, 2022 and was most recently updated on October 24th, 2022."
Answered by AI
Who else is applying?
What state do they live in?
California
What portion of applicants met pre-screening criteria?
Did not meet criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger